Cantor Fitzgerald analyst Charles Duncan initiated coverage of Karuna Therapeutics with a Neutral rating and $214 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRTX:
- Karuna Therapeutics price target lowered to $257 from $262 at Wells Fargo
- Karuna Therapeutics reports Q4 EPS ($2.22), consensus ($2.25)
- Karuna Therapeutics signing exclusive global license agreement for TRPC4/5
- Karuna Therapeutics appoints William Kane as Chief Commercial Officer
- Karuna Therapeutics initiated with a Neutral at UBS